Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?

Luo, Hao; Fang, Fu Min; Kang, Chih Hsiung; Chuang, Yao‐Chi; Chiang, Po‐Hui

doi:10.1007/s11255-012-0277-y

Cited by 9 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few absolute contraindications to undergoing HDR brachytherapy, and in each situation the extra risks of toxicity associated with the above need to be considered in the light of other treatment options and patient preference. For example, while patients who have had a previous TURP or large prostate volume are excluded from most brachytherapy clinical trial protocols, many experienced practitioners will often still treat these patients with HDR, sometimes with minor modifications of technique with excellent results ( 9 ). Similarly, for patients with inflammatory bowel disease, brachytherapy results in less rectal dose than EBRT so may be the preferred treatment technique.…”

Section: Rationalementioning

confidence: 99%

High dose-rate brachytherapy in the treatment of prostate cancer

Mendez

Morton

2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

High dose-rate (HDR) brachytherapy involves delivery of a high dose of radiation to the cancer with great sparing of surrounding organs at risk. Prostate cancer is thought to be particularly sensitive to radiation delivered at high dose-rate or at high dose per fraction. The rapid delivery and high conformality of dose results in lower toxicity than that seen with low dose-rate (LDR) implants. HDR combined with external beam radiotherapy results in higher cancer control rate than external beam only, and should be offered to eligible high and intermediate risk patients. While a variety of dose and fractionations have been used, a single 15 Gy HDR combined with 40–50 Gy external beam radiotherapy results in a disease-free survival of over 90% for intermediate risk and 80% for high risk. HDR monotherapy in two or more fractions (e.g., 27 Gy in 2 fractions or 34.5 Gy in 3) is emerging as a viable alternative to LDR brachytherapy for low and low-intermediate risk patients, and has less toxicity. The role of single fraction monotherapy to a dose of 19–20 Gy is evolving, with some conflicting data to date. HDR should also be considered as a salvage approach for recurrent disease following previous external beam radiotherapy. A particular advantage of HDR in this setting is the ease of delivering focal treatments, which combined with modern imaging allows focal dose escalation with minimal toxicity. Trans-rectal ultrasound (TRUS) based planning is replacing CT-based planning as the technique of choice as it minimizes or eliminates the need to move the patient between insertion, planning and treatment delivery, thus ensuring high accuracy and reproducibility of treatment.

show abstract

Section: Rationalementioning

confidence: 99%

High dose-rate brachytherapy in the treatment of prostate cancer

Mendez

Morton

2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Although the baseline urinary function can be predictive for functional outcome following HDR BRT, 61 neither larger glandular size nor previous transurethral resection of the prostate (TURP) (given a sufficient amount of time has surpassed [>3 months] and residual gland volume remains for image‐based 3D treatment planning), 62 , 63 , 64 should be considered as absolute contraindications.…”

Section: Introductionmentioning

confidence: 99%

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

et al. 2021

View full text Add to dashboard Cite

Background: High-dose-rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas.Recent findings: This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion:Valid long-term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery.

show abstract

High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer

Tselis

Zamboglou

2014

Radiotherapy in Prostate Cancer

View full text Add to dashboard Cite

Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?

Cited by 9 publications

References 22 publications

High dose-rate brachytherapy in the treatment of prostate cancer

High dose-rate brachytherapy in the treatment of prostate cancer

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

High-Dose-Rate Brachytherapy in the Treatment of Clinically Localized Prostate Cancer

Contact Info

Product

Resources

About